VanEck Biotech ETF(BBH · ETF)
ETF quote, holdings, sector allocation, technicals, and options analytics.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
- 52-Week Range
- $150.18 – $202.91
- YTD
- -2.21%
- IV Rank (30D)
- 2.93
- Straddle Price
- $10.90
- P/C Vol Ratio
- 0.59
VanEck Biotech ETF (BBH) ETF
- Exchange
- XNAS
- Inception
- 2011-12-20
- Has Options
- Yes
| Ex-Date | Pay Date | Amount | Type |
|---|---|---|---|
| 2025-12-22 | 2025-12-26 | $0.9565 | CD |
| 2024-12-23 | 2024-12-24 | $1.2517 | CD |
| 2023-12-18 | 2023-12-22 | $0.7127 | CD |
| 2022-12-19 | 2022-12-23 | $0.7488 | CD |
| 2021-12-20 | 2021-12-27 | $0.3972 | CD |
| Symbol | Name | Weight % | Asset Class | Country |
|---|---|---|---|---|
| AMGN | Amgen Inc | 14.47% | Equity (US) | — |
| GILD | Gilead Sciences Inc | 13.57% | Equity (US) | — |
| VRTX | Vertex Pharmaceuticals Inc | 8.07% | Equity (US) | — |
| ARGX | Argenx Se | 6.45% | Equity (US) | — |
| REGN | Regeneron Pharmaceuticals Inc | 6.19% | Equity (US) | — |
| IQV | Iqvia Holdings Inc | 4.63% | Equity (US) | — |
| RVMD | Revolution Medicines Inc | 4.40% | Equity (US) | — |
| NTRA | Natera Inc | 4.29% | Equity (US) | — |
| BIIB | Biogen Inc | 3.97% | Equity (US) | — |
| ALNY | Alnylam Pharmaceuticals Inc | 3.77% | Equity (US) | — |
| UTHR | United Therapeutics Corp | 3.53% | Equity (US) | — |
| ILMN | Illumina Inc | 3.29% | Equity (US) | — |
| ONC | Beone Medicines Ltd | 2.96% | Equity (US) | — |
| MRNA | Moderna Inc | 2.90% | Equity (US) | — |
| INSM | Insmed Inc | 2.65% | Equity (US) | — |
| INCY | Incyte Corp | 2.45% | Equity (US) | — |
| NBIX | Neurocrine Biosciences Inc | 2.41% | Equity (US) | — |
| BNTX | Biontech Se | 2.14% | Equity (US) | — |
| ICLR | Icon Plc | 1.72% | Equity (US) | — |
| BMRN | Biomarin Pharmaceutical Inc | 1.40% | Equity (US) | — |
| CRL | Charles River Laboratories Internationa | 1.35% | Equity (US) | — |
| TECH | Bio-Techne Corp | 1.34% | Equity (US) | — |
| QGEN | Qiagen Nv | 1.05% | Equity (US) | — |
| TEM | Tempus Ai Inc | 0.95% | Equity (US) | — |
| — | Cash | 0.09% | Cash/Money Market | — |
| — | Other/Cash | -0.02% | Cash/Money Market | — |
| # | Symbol | Issuer | Weight | Value |
|---|---|---|---|---|
| 1 | Amgen Inc | Amgen Inc | 15.09% | $56.7M |
| 2 | Gilead Sciences Inc | Gilead Sciences Inc | 14.38% | $54.0M |
| 3 | Vertex Pharmaceuticals Inc | Vertex Pharmaceuticals Inc | 9.12% | $34.3M |
| 4 | Regeneron Pharmaceuticals Inc | Regeneron Pharmaceuticals Inc | 7.73% | $29.0M |
| 5 | Argenx SE | Argenx SE | 4.72% | $17.7M |
| 6 | IQVIA Holdings Inc | IQVIA Holdings Inc | 4.55% | $17.1M |
| 7 | Alnylam Pharmaceuticals Inc | Alnylam Pharmaceuticals Inc | 4.42% | $16.6M |
| 8 | Natera Inc | Natera Inc | 4.28% | $16.1M |
| 9 | Insmed Inc | Insmed Inc | 4.12% | $15.5M |
| 10 | BeOne Medicines Ltd | BeOne Medicines Ltd | 3.17% | $11.9M |
| 11 | Biogen Inc | Biogen Inc | 3.16% | $11.9M |
| 12 | United Therapeutics Corp | United Therapeutics Corp | 2.97% | $11.2M |
| 13 | Illumina Inc | Illumina Inc | 2.61% | $9.8M |
| 14 | ICON PLC | ICON PLC | 2.46% | $9.2M |
| 15 | Exact Sciences Corp | Exact Sciences Corp | 2.20% | $8.3M |
| 16 | Incyte Corp | Incyte Corp | 1.96% | $7.4M |
| 17 | Neurocrine Biosciences Inc | Neurocrine Biosciences Inc | 1.95% | $7.3M |
| 18 | BioNTech SE | BioNTech SE | 1.82% | $6.8M |
| 19 | Moderna Inc | Moderna Inc | 1.59% | $6.0M |
| 20 | Charles River Laboratories International Inc | Charles River Laboratories International Inc | 1.39% | $5.2M |
| 21 | Bio-Techne Corp | Bio-Techne Corp | 1.32% | $4.9M |
| 22 | Repligen Corp | Repligen Corp | 1.31% | $4.9M |
| 23 | QIAGEN NV | QIAGEN NV | 1.27% | $4.8M |
| 24 | BioMarin Pharmaceutical Inc | BioMarin Pharmaceutical Inc | 1.22% | $4.6M |
| 25 | Tempus AI Inc | Tempus AI Inc | 1.09% | $4.1M |
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | +2.15% | 23 |
| Feb | -0.58% | 23 |
| Mar | +0.38% | 23 |
| Apr | -0.14% | 23 |
| May | +0.97% | 23 |
| Jun | +1.11% | 23 |
| Jul | +4.79% | 22 |
| Aug | -0.01% | 22 |
| Sep | -0.43% | 22 |
| Oct | -0.30% | 22 |
| Nov | +2.89% | 22 |
| Dec | -0.71% | 22 |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
- IV Rank (30D)
- 2.93
- IV Rank (7D)
- 64.78
- Avg IV
- 24.0%
- Straddle (30D)
- $10.90
- Straddle (7D)
- $6.05
- P/C Volume
- 0.59
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
RR25 and BF25 from the live options chain. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Enter a ticker to render the implied volatility surface.
- Beta (1Y vs SPY)
- 0.72
- Correlation (SPY)
- 45.3%
- R²
- 0.21
- Ann. Volatility
- 19.1%
- SPY Volatility
- 12.1%
Low volatility - stock moves less than market
Click any bar to view the full quote for that stock.
| Symbol | Price | 1 Day | 1 Week | 1 Month |
|---|